GRAIL, Inc. (GRAL) Revenue by Segment & Business Profile
Screening Revenue was 95.4% of GRAIL, Inc.'s revenue across the 2 lines it reports, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
GRALGRAIL, Inc.Follow GRAL — free
—
Price chart with a free account
- Market cap
- 5.9B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 4 Nov, in 11 days
What the company does
GRAIL, Inc. is a diagnostics & research company in the healthcare sector. In its SEC filings it reports 2 business lines: Screening Revenue (95%), Developmental Services Revenue (5%). Trailing twelve-month revenue: $165.3 million as of 2026-06-30.
Roles we read
from the filings, not the sector label- Clinical diagnostics
Revenue by geography
latest quarter · company segment note| Region | Revenue | Share | y/y |
|---|---|---|---|
| United States | 42M | 93.2% | +21.8% |
| Outside the US | 3M | 6.8% | +127.5% |
GRAIL, Inc. — questions
- What does GRAIL, Inc. do?
- GRAIL, Inc. is a diagnostics & research company in the healthcare sector. In its SEC filings it reports 2 business lines: Screening Revenue (95%), Developmental Services Revenue (5%). Trailing twelve-month revenue: $165.3 million as of 2026-06-30.
- How does GRAIL, Inc. make money?
- By the lines it reports in its SEC filings: Screening Revenue 95.4%, Developmental Services Revenue 4.6% of revenue.
Every figure on this page comes from GRAIL, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.